SI0781778T1 - Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy - Google Patents

Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy

Info

Publication number
SI0781778T1
SI0781778T1 SI9630480T SI9630480T SI0781778T1 SI 0781778 T1 SI0781778 T1 SI 0781778T1 SI 9630480 T SI9630480 T SI 9630480T SI 9630480 T SI9630480 T SI 9630480T SI 0781778 T1 SI0781778 T1 SI 0781778T1
Authority
SI
Slovenia
Prior art keywords
paclitaxel
beta
prodrugs
prodrug
preparation
Prior art date
Application number
SI9630480T
Other languages
English (en)
Slovenian (sl)
Inventor
Bont Hendricus Barthelomeas Andreas De
Hidde Jacob Haisma
Ruben Geradus George Leenders
Vos Dick De
Johan Wilhelm Scheeren
Original Assignee
Pharmachemie B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmachemie B.V. filed Critical Pharmachemie B.V.
Publication of SI0781778T1 publication Critical patent/SI0781778T1/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C263/00—Preparation of derivatives of isocyanic acid
    • C07C263/12—Preparation of derivatives of isocyanic acid from or via nitrogen analogues of carboxylic acids, e.g. from hydroxamic acids, involving a Hofmann, Curtius or Lossen-type rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI9630480T 1995-12-29 1996-12-17 Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy SI0781778T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203671 1995-12-29
EP96203571A EP0781778B1 (en) 1995-12-29 1996-12-17 Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy

Publications (1)

Publication Number Publication Date
SI0781778T1 true SI0781778T1 (en) 2002-10-31

Family

ID=8221031

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630480T SI0781778T1 (en) 1995-12-29 1996-12-17 Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy

Country Status (10)

Country Link
US (1) US5760072A (xx)
EP (1) EP0781778B1 (xx)
JP (1) JPH09202796A (xx)
AT (1) ATE216394T1 (xx)
CA (1) CA2192424C (xx)
DE (1) DE69620727T2 (xx)
DK (1) DK0781778T3 (xx)
ES (1) ES2175028T3 (xx)
PT (1) PT781778E (xx)
SI (1) SI0781778T1 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038727A1 (fr) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Composite medicamenteux
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
JP4153660B2 (ja) * 1997-10-08 2008-09-24 株式会社横浜国際バイオ研究所 タキソイド誘導体およびその製造方法
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US20050192360A1 (en) * 1999-04-14 2005-09-01 Li Chiang J. Method of treatment of pancreatic cancer
US20050222246A1 (en) * 1999-04-14 2005-10-06 Li Chiang J Beta-lapachone is a broad spectrum anti-cancer agent
AU7007001A (en) 2000-06-22 2002-01-02 Nitromed Inc Nitrosated and nitrosylated taxanes, compositions and methods of use
US7070797B2 (en) * 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US20050197405A1 (en) * 2000-11-07 2005-09-08 Li Chiang J. Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
MXPA03011094A (es) * 2001-05-31 2004-12-06 Medarex Inc Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6816571B2 (en) * 2002-02-06 2004-11-09 L-3 Communications Security And Detection Systems Corporation Delaware Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner
EP1487460A2 (en) 2002-02-28 2004-12-22 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
US20050107310A1 (en) * 2002-03-19 2005-05-19 Holick Michael F. Carboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
CA2490626A1 (en) * 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. Prodrug, medicinal utilization thereof and process for producing the same
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
US20050192247A1 (en) * 2004-02-23 2005-09-01 Li Chiang J. Method of treating cancers
WO2006042056A2 (en) * 2004-10-08 2006-04-20 The Ohio State University Methods and compositions for enzyme-specific activation of carbohydrate-conjugated prodrugs
FR2947455B1 (fr) 2009-07-01 2014-01-03 Centre Nat Rech Scient La dermaseptine b2 comme inhibiteur de la croissance tumorale
CN110227164B (zh) * 2018-03-06 2021-11-23 江苏吉贝尔药业股份有限公司 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
EP4175966A1 (en) * 2020-07-06 2023-05-10 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Polymeric micelles comprising glucuronide-prodrugs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol

Also Published As

Publication number Publication date
ATE216394T1 (de) 2002-05-15
US5760072A (en) 1998-06-02
CA2192424A1 (en) 1997-06-30
JPH09202796A (ja) 1997-08-05
CA2192424C (en) 2002-01-22
DK0781778T3 (da) 2002-06-17
DE69620727D1 (de) 2002-05-23
EP0781778B1 (en) 2002-04-17
DE69620727T2 (de) 2002-08-22
ES2175028T3 (es) 2002-11-16
PT781778E (pt) 2002-08-30
EP0781778A1 (en) 1997-07-02

Similar Documents

Publication Publication Date Title
SI0781778T1 (en) Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
AU735243B2 (en) Peptidyl prodrugs and methods of making and using the same
CA2336815A1 (en) Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
WO2002007759A3 (en) Clostridial toxin derivatives and methods for treating pain
IL133585A0 (en) Soluble prodrugs of paclitaxel
PT1183050E (pt) Processo para a produção de uma preparação farmacêutica injectável
CA2455774A1 (en) Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
WO1998000172A3 (en) Compositions and methods for altering the biodistribution of biological agents
WO1988000837A3 (en) Advanced anticancer therapy and cytotoxic medicaments for its implementation
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
CA2211118A1 (en) Stable lipid-comprising drug delivery complexes and methods for their production
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ505339A (en) Camptothecin tetracyclic derivatives useful for inhibiting topoisomerase I and/or II pyridine intermediates thereof
CA2282082A1 (fr) Microgranules contenant du cisplatine
WO2000001376A3 (en) Pharmaceutical compositions and their uses for treatment of demyelinating disorders
AU1313095A (en) Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role
DE69533615D1 (de) Anthracyclin Prodrugs, Verfahren zu deren Herstellung und deren Verwendung in der selektiven Chemotherapie
WO2001092273A3 (en) Benzenedicarboxylic acid derivatives
WO2005025512A3 (en) Cobalamin conjugates for anti-tumor therapy
WO2003100031A3 (en) Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2083377A1 (en) Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna
DE69031932T2 (de) Arylsulfatase
AU5819296A (en) Pharmaceutical composition prepared by addition of a flavour vehicle to a medicament